Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 217–240 of 297
Senescent Cells Define Aggressive Endometriosis Subtype
A correction to prior research clarifies the classification of an aggressive endometriosis subtype characterized by cellular senescence and immune modulation. The findings refine understanding of how aging-related cellular changes drive pathological remodeling in endometrial tissue, with implications for stratifying disease severity and treatment response.
Life Biosciences lands $80m to push cell reset therapy
Life Biosciences secured $80 million to advance ER-100, the first partial epigenetic reprogramming therapy entering human trials, designed to restore cellular function in age-damaged neurons. This represents a shift in aging intervention from symptom management toward addressing the underlying cellular decline that drives multiple age-related diseases.
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Life Biosciences' ER-100, a cellular reprogramming therapy, has received FDA clearance for human trials targeting optic nerve disorders. The trial represents a regulatory shift toward rejuvenation-based approaches, potentially positioning cellular age-reversal technologies within mainstream clinical frameworks rather than relegating aging to inevitability.
Morphofunctional Heterogeneity and Plasticity of Glioblastoma Cells Induced to Senescence by Temozolomide
Temozolomide-induced senescent glioblastoma cells exhibit dynamic morphological states with distinct survival mechanisms and drug sensitivities. This heterogeneity and plasticity have direct implications for how chemotherapy resistance develops and why combination senotherapeutic strategies may be necessary to prevent tumor recurrence.
NK Cell Therapy Targets Immune Dysfunction in Neurodegeneration
NKGen Biotech is advancing Troculeucel, an autologous natural killer cell therapy, through Phase 2 trials for Alzheimer's disease with expansion into other neurodegenerative conditions. The approach targets immune system dysfunction in neurodegeneration, representing a distinct mechanistic pathway from conventional pharmacological interventions.
Cardiac Fibrosis Reversal: RNA Therapy Targets Aging Cell Behavior
HAYA Therapeutics received FDA Fast Track designation for HTX-001, an RNA-based therapy designed to reprogram fibroblasts and reverse cardiac fibrosis rather than manage heart disease symptoms. This regulatory milestone signals a shift toward cellular reprogramming as a mechanism for addressing age-related organ stiffening and dysfunction.
Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging
Senescent hepatocytes in aging release extracellular vesicles containing microRNAs that enhance metastatic potential across multiple cancer types in aged organisms. This mechanism directly links hepatic aging to systemic cancer progression, identifying a previously uncharacterized pathway connecting liver dysfunction to increased metastatic risk in older adults.
Thymulin Restores Immune Function in Aging Cancer Models
Thymulin, a hormone produced by the thymus gland, reduces systemic inflammation in aging mice and enhances the effectiveness of cancer treatments. The research identifies thymulin as a circulating factor capable of modulating age-related immune dysfunction independently of full immune system rejuvenation.
Protein Aggregates Targeted in First Human Longevity Trial
Retro Biosciences, valued at $1.8 billion, has advanced an oral therapeutic into human trials that targets protein aggregate clearance—a mechanism implicated in Alzheimer's pathology. Early safety data show no dose-limiting toxicities, positioning the company to release efficacy findings in 2026 and marking a critical inflection from bench research to clinical validation in longevity therapeutics.
Ultrasound Gene Delivery Solves Repeat Treatment Problem
SonoThera's ultrasound-based gene delivery platform addresses a fundamental constraint in genetic medicine: the inability to repeat treatments and the size limitations of viral vectors. The technology uses microbubbles and targeted ultrasound to open cellular pathways without immune recognition, potentially enabling the repeated interventions required for aging-related therapies.
Why aging feels harder after 40
Circulating stem cell count declines sharply after age 30, reducing tissue repair capacity and resilience. This decline correlates with recovery time, injury healing, and disease risk—making stem cell abundance a measurable predictor of healthspan independent of conventional longevity markers.
KIF14 Loss Drives Egg Aging Through Energy Failure
Declining levels of the kinesin protein KIF14 impair egg cell quality during reproductive aging by disrupting both the cellular scaffold and mitochondrial function. This mechanism reveals a specific molecular pathway linking reproductive senescence to energy production failure, with direct implications for fertility outcomes across the reproductive lifespan.
CD47 Platelets Suppress Aging Inflammation in Centenarians
Centenarians carry genetic and platelet-based mechanisms that suppress age-related inflammation through CD47 expression, which dampens monocyte activation. The LAV-BPIFB4 variant drives this protective effect, and recombinant administration of the protein replicates these benefits in non-carriers, establishing a translatable therapeutic target for inflammaging and cardiovascular disease.
Dog Gene Therapy Shows Early Safety in Aging Trial
Genflow Biosciences reports early safety and survival benefits in its SLAB gene therapy trial in 24 aging beagles, with no adverse events observed at three months. The study represents an emerging model in longevity research: using companion animals as a translational bridge between laboratory studies and human trials, where faster aging enables observation of long-term changes within years rather than decades.
Kidney Regeneration Surgery: Restoring Function, Not Managing Decline
Rokit Healthcare has received clinical approval to begin the first human kidney regeneration surgery using autologous omentum-derived cells combined with AI-assisted 3D bioprinting and robotic surgery, with trials starting July 2026. This represents a shift from chronic kidney disease management toward actual tissue regeneration, with potential to restore organ function rather than manage decline.
Restoring Lysosomal Clearance Targets Parkinson's Root Cause
Researchers identified a protein that restores lysosomal clearance of alpha-synuclein, the pathogenic protein driving Parkinson's disease. This addresses a fundamental breakdown in cellular protein quality control that accelerates neurodegeneration with age.
Senescence at the crossroads of postpartum remodeling and tumorigenesis
Cellular senescence plays a dual role in postpartum mammary gland remodeling—supporting normal tissue reorganization while simultaneously creating conditions that enhance tumor progression when oncogenic events coincide with gland involution. This mechanism reveals how a normally protective cellular state becomes pathogenic under specific developmental and genetic circumstances.
Testing the redox theory of aging under parasitism
Parasitic infection accelerates oxidative stress and aging markers in host organisms, providing empirical support for redox-based aging mechanisms. This finding illuminates how chronic pathogenic burden compounds systemic dysfunction and accelerates cellular deterioration through reactive oxygen species accumulation.
Extracellular matrix: new insights into its role in female reproductive aging and potential therapeutic strategies
The extracellular matrix—the structural scaffold surrounding reproductive tissues—undergoes progressive degradation during female reproductive aging, compromising ovarian function and fertility. Targeting matrix preservation and remodeling represents a mechanistic approach to extending reproductive lifespan and potentially supporting broader aging-related outcomes.
RANKL Inhibition Reverses Bone Loss and Extends Lifespan
RANKL targeting—via genetic deletion or antibody neutralization—reverses bone loss, restores muscle function, and extends lifespan in a mouse model of Hutchinson-Gilford progeria. This suggests RANKL inhibition may address the accelerated tissue degeneration characteristic of this premature aging syndrome.
Engineered fat cells deliver multi-year gene therapies
Remedium Bio secured $10 million in Series A funding to advance gene therapies designed for durable, long-lasting protein production using engineered fat cells as a therapeutic depot. The platform targets chronic diseases across endocrinology, immunology, neurology, musculoskeletal, and cardiometabolic domains with single-injection, adjustable dosing.
Integrin‐Binding Matricellular Protein Fibulin‐5 Maintains Epidermal Stem Cell Heterogeneity During Skin Aging
Fibulin-5, an extracellular matrix protein that declines with age, maintains epidermal stem cell function by activating YAP signaling through integrin binding. Loss of fibulin-5 reproduces age-associated changes in skin stem cell populations, identifying a molecular mechanism linking extracellular environment degradation to cellular aging.
Human cGAS Drives LINE‐1 Transcriptional Activation to Trigger MAVS‐Dependent Cellular Senescence
Human cGAS activates LINE-1 retrotransposon transcription through upregulation of CTCF and RUNX3, triggering cellular senescence via MAVS-dependent RNA sensing. This human-specific pathway reveals a mechanism linking genomic surveillance to accelerated cellular aging, with direct implications for understanding senescence in aging and age-related disease.
Aspen wins official name for Parkinson’s cell therapy candidate
Aspen Neuroscience received WHO and AMA approval for the official name Sasineprocel for its autologous dopaminergic cell therapy derived from patient skin cells. The therapy aims to restore dopamine-producing neurons in Parkinson's disease without immunosuppression, currently in Phase 1/2a trials.